Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study

被引：2

作者：

Furubayashi, Nobuki ^{[1
]}

Morokuma, Futoshi ^{[2
]}

Tomoda, Toshihisa ^{[3
]}

Hori, Yoshifumi ^{[4
]}

Negishi, Takahito ^{[1
]}

Miura, Akihiro ^{[1
]}

Komori, Hiroki ^{[1
]}

Kuroiwa, Kentaro ^{[4
]}

Nakamura, Motonobu ^{[1
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept Urol, Fukuoka, Japan

[2] Saga Ken Med Ctr Koseikan, Dept Urol, Saga, Japan

[3] Oita Prefectural Hosp, Dept Urol, Oita, Japan

[4] Miyazaki Prefectural Miyazaki Hosp, Dept Urol, Miyazaki, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 03期

关键词：

chemotherapy pembrolizumab; real -world clinical practice; Advanced urothelial carcinoma; platinum-based; IMMUNE CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; GEMCITABINE; CARBOPLATIN; CISPLATIN; CANCER; TUMORS; CELLS;

D O I：

10.21873/anticanres.15631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear. Patients and Methods: Thirty-four patients who received pembrolizumab as second-line treatment after firstline platinum-based chemotherapy were retrospectively evaluated. Results: According to overall survival (OS) from pembrolizumab, there was a significant difference between <= 4 and 0.001), but not between <= 6 and 6 cycles (18.6 and 27.3 months, p=0.276). Conclusion: The optimal timing of switching from platinum-base chemotherapy to pembrolizumab in advanced UC is around six cycles.

引用

页码：1571 / 1577

页数：7

共 23 条

[1] Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report [J].

Azuma, Takeshi ;

Sugihara, Tohru ;

Honda, Sachi ;

Yoshizaki, Uran ;

Nimi, Fusako ;

Tsuru, Ibuki ;

Kume, Haruki .

ONCOLOGY LETTERS, 2019, 17 (04) :4011-4015

[2] The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma - A Phase II study of the Hellenic Cooperative Oncology Group [J].

Bamias, A ;

Moulopoulos, LA ;

Koutras, A ;

Aravantinos, G ;

Fountzilas, G ;

Pectasides, D ;

Kastritis, E ;

Gika, D ;

Skarlos, D ;

Linardou, H ;

Kalofonos, HP ;

Dimopoulos, MA .

CANCER, 2006, 106 (02) :297-303

[3] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[4] Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma [J].

Galsky, M. D. ;

Chen, G. J. ;

Oh, W. K. ;

Bellmunt, J. ;

Roth, B. J. ;

Petrioli, R. ;

Dogliotti, L. ;

Dreicer, R. ;

Sonpavde, G. .

ANNALS OF ONCOLOGY, 2012, 23 (02) :406-410

[5] CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative [J].

Ghiringhelli, F ;

Larmonier, N ;

Schmitt, E ;

Parcellier, A ;

Cathelin, D ;

Garrido, C ;

Chauffert, B ;

Solary, E ;

Bonnotte, B ;

Martin, F .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (02) :336-344

[6] Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen [J].

Gravis, Gwenaelle ;

Billon, Emilien ;

Baldini, Capucine ;

Massard, Christophe ;

Hilgers, Werner ;

Delva, Remy ;

Walz, Jochen ;

Pignot, Geraldine ;

Rybikowski, Stanislas ;

Dermeche, Slimane ;

Thomassin, Jeanne ;

Brunelle, Serge ;

Lavaud, Pernelle ;

Loriot, Yohann .

EUROPEAN JOURNAL OF CANCER, 2018, 104 :236-238

[7] Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab [J].

Kato, Minoru ;

Kobayashi, Takashi ;

Matsui, Yoshiyuki ;

Ito, Katsuhiro ;

Hikami, Kensuke ;

Yamada, Takeshi ;

Ogawa, Kosuke ;

Nakamura, Kenji ;

Sassa, Naoto ;

Yokomizo, Akira ;

Abe, Takashige ;

Tsuchihashi, Kazunari ;

Tatarano, Shuichi ;

Inokuchi, Junichi ;

Tomida, Ryotaro ;

Fujiwara, Maki ;

Takahashi, Atsushi ;

Matsumoto, Kazumasa ;

Shimizu, Kosuke ;

Araki, Hiromasa ;

Kurahashi, Ryoma ;

Ozaki, Yu ;

Tashiro, Yu ;

Uegaki, Masayuki ;

Kojima, Takahiro ;

Uchida, Junji ;

Ogawa, Osamu ;

Nishiyama, Hiroyuki ;

Kitamura, Hiroshi .

INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (12) :1261-1267

[8] The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours [J].

Moch, Holger ;

Cubilla, Antonio L. ;

Humphrey, Peter A. ;

Reuter, Victor E. ;

Ulbright, Thomas M. .

EUROPEAN UROLOGY, 2016, 70 (01) :93-105

[9] Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis [J].

Necchi, Andrea ;

Pond, Gregory R. ;

Raggi, Daniele ;

Giannatempo, Patrizia ;

Vogelzang, Nicholas J. ;

Grivas, Petros ;

Galsky, Matthew D. ;

Bellmunt, Joaquim ;

Sonpavde, Guru .

CLINICAL GENITOURINARY CANCER, 2017, 15 (01) :23-30

[10] Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs [J].

Ohtsukasa, S ;

Okabe, S ;

Yamashita, H ;

Iwai, T ;

Sugihara, K .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (12) :719-726

← 1 2 3 →